Navigation Links
InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
Date:9/30/2009

LOS ALTOS, Calif., Sept. 30 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today positive results for INT131 in a 24 week Phase 2b study at the 45th European Association for the Study of Diabetes Meeting in Vienna, Austria. An overview of the data will be presented at 1:45 PM Friday, October 2, 2009 by InteKrin Therapeutics' Chief Medical Officer, Alex DePaoli, MD. His presentation is entitled "Impact of INT131 Besylate, a Selective PPAR-gamma Modulator (SPPARM), on Glycemic Control in Patients with Type 2 Diabetes in a 24-Week Phase 2b Study (INT131-007)." In this study INT131 demonstrated a superior side effect profile with comparable efficacy when tested side-by-side against 45 mgs daily pioglitazone (Actos®).

"INT131 provided potent glucose lowering with minimal body weight gain, hematocrit reduction, or evidence of edema at 1 mg, replicating the results of the earlier 4-week Phase 2a study," said Dr. DePaoli. "These data validate the activity of INT131 as a potent selective PPAR-gamma modulator (SPPARM) with significant glucose lowering properties and without the edema or degree of body weight gain seen with pioglitazone." There was no difference in incidence or severity of edema in any INT131 dose group compared to placebo, while the expected increase in frequency and severity of edema was observed in the pioglitazone group.

"These data confirm INT131 to be an advance for patients who suffer with this disease," noted Denny Lanfear, InteKrin President and Chief Executive Officer. "As diabetes has become an epidemic throughout the world, physicians desperately need a safe insulin sensitizer in their diabetes therapeutic armamentarium that does not have the safety and tolerability shortcomings of the existing therapies."

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. INT131 has
'/>"/>

SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
2. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
3. Reportlinker Adds Stem Cell Therapeutics Markets Report
4. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
5. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
6. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
7. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
8. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
9. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
10. Orexigen(R) Therapeutics to Speak at UBS Global Life Sciences Conference
11. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... | RBJ today announces the firm brokered a long-term lease ... leading biopharmaceutical company, at Two Ledgemont Center in ... , president, and Brian Cohen , senior vice president, ... at 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... Boulder, CO / Rootstown, OH (PRWEB) January 22, 2015 ... sensitive detection platform, announced today that it has received AOAC-PTM ... O26, O45, O1O3, O111, O121, and O145; collectively referred to ... (E. coli) O157, at 1 colony forming unit (cfu) per ...
(Date:1/22/2015)... 2015 Controlled Substance Compliance Services (CSCS), ... companies check the legal requirements around using controlled substances ... , As their international operations expand and become ... solutions built as a result of the first phase ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
Breaking Biology Technology:Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
... Renewable Natural Gas ... and Other Waste Products, TARRYTOWN, N.Y., June 11 ... in the renewable bioenergy industry,will today mark the commencement ... a ground breaking ceremony. The Dublin, Texas,facility, owned and ...
... June 11 WellCentive today announced the ... is now a part of its,popular online ... Atlanta-based WellCentive (http://www.wellcentive.com ) provides ... registry system for,physicians, physician organizations, health insurance ...
... in Animal Models of ... Arthritis - ... SAN DIEGO, June 11 Ardea Biosciences, Inc.,(Nasdaq: RDEA ) today announced ... RDEA119, demonstrating,its potent activity in animal models of arthritis. In addition, the Company,will ...
Cached Biology Technology:Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 2Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 3Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 4Environmental Power Holds Ground Breaking Ceremony for Renewable Natural Gas Facility at Rio Leche Estates 5WellCentive Launches New Secure Messaging Platform for Its Patient Registry System 2WellCentive Launches New Secure Messaging Platform for Its Patient Registry System 3Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 2Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 3Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 4Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology 5
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 The ... it easier to detect and prevent counterfeit microcircuits from ... agency started performing an in-house microcircuit anti-counterfeit initiative dubbed ... purchased microcircuits while increasing their reliability throughout the supply ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... 12, 2009 An international conference that will explore ... University May 25-29. It is being organized to coincide ... On the Origin of Species, (and the 200th anniversaryspecifically, ... Einstein of biology," says Ralph Pudritz, director of McMaster,s ...
... CITYUnraveling the genetics of social behavior and cognitive abilities, ... Institute for Biological Studies have traced the role of ... known as Williams Syndrome. Their results, published ... American Journal of Medical Genetics , suggest that ...
... -- The rangelands of Iran have one of the world,s ... technological developments and knowledge of the soil that has produced ... an increasing population of humans and livestock in the region ... suggests that the soil is rapidly degrading. With the land ...
Cached Biology News:2 genes influence social behavior, visual-spatial performance in people with Williams syndrome 22 genes influence social behavior, visual-spatial performance in people with Williams syndrome 3Preventing rangeland erosion: Developing better management practices in Iran 2
In Western blotting antibodies recognize 94 K protein band, which corresponds to S-layer protein...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
The VersArray hybridization chamber is used for manual (coverslip) hybridization of microarrays. The chamber accommodates 2 slides and is watertight to allow incubation of slides in a water bath. Dim...
... PROTECT FROM LIGHT. Useful in cell activation experiments when ... by TLC. Soluble in DMSO or EtOH. ... mM stock in DMSO is recommended. Microliter amounts of ... with rapid mixing (e.g. 10 μl into 5 ml ...
Biology Products: